Impact of Pulmonary Follow-up After Stem Cell Graft

Completed

• Conditions: Hematologic Neoplasms

• Registration Number: NCT03349372
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Allogeneic hematopoietic stem cell transplantation is the only possible treatment for many malignant and non-malignant hemopathies. The graft-versus-host immunological reaction (GvH) is a frequent and sometimes serious complication. The objective is to study whether a systematic and early follow-up by a lung specialist of allografted patients would allow an earlier diagnosis of GvH with pulmonary complications.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-11-01
• Primary Completion: 2017-10-31
• Study Completion: 2017-10-31
• Status Verified: 2017-11
• Study First Submitted: 2017-11-17
• Study First Submitted QC: 2017-11-17
• Last Update Submitted: 2017-11-17
• Study First Posted: 2017-11-21
• Last Update Posted: 2017-11-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 227

Inclusion Criteria

• 18 years of age or older
• patients with a hematopoietic stem cell transplantation

Read More

Exclusion Criteria

• Death within 100 days post-surgery

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Medical complications	Medical complications, especially Graft-versus-Host reaction with pulmonary complications occurring within 100 days post-surgery are studied	100 days after allograft

Trial Locations

Locations (1)

Croix-Rousse Hospital, Hospices Civils de Lyon; 🇫🇷 Lyon, France